At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Pulmatrix, Inc. (NASDAQ: PULM) will give a presentation at the 2016 Aegis Growth Conference at The Encore at Wynn Las Vegas in Nevada on Wednesday, September 21, 2016 at 10:00 AM PDT. Pulmatrix...
Pulmatrix, Inc. (NASDAQ: PULM) will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12, 2016 at 5:30 PM EDT in the Lotte New York Palace Hotel in New...
Pulmatrix, Inc. (NASDAQ: PULM) announced today that the U.S. Food & Drug Administration has granted the company's request for orphan drug status for its inhaled drug for treating pulmonary fungal...
Pulmatrix, Inc. (NASDAQ: PULM) today reports its second quarter financial results and provides an update on the progress of its drug development pipeline. "In the first half of the year, we...
Pulmatrix, Inc. (NASDAQ: PULM), today announced positive topline data from a Phase 1 pilot pharmacokinetic bioavailability trial of PUR0200. PUR0200 is a novel dry powder formulation of a...
Pulmatrix, Inc. (NASDAQ: PULM), a pharmaceutical company developing innovative inhaled drugs, today announced that Chief Executive Officer Robert Clarke, PhD, has described advances in inhaled...
Pulmatrix, Inc., (NASDAQ: PULM), a pharmaceutical company developing innovative inhaled drugs today announced the release of an animated life sciences video [ir.pulmatrix.com] to raise awareness...
Pulmatrix, Inc., (NASDAQ: PULM), a specialty pharmaceutical company developing innovative inhaled drugs, announced today that it was added to the Russell Microcap Index when Russell Investments...
Pulmatrix (NASDAQ:PULM), a specialty pharmaceutical company developing novel inhaled therapeutic formulations based on the company's proprietary iSPERSE™ technology, has completed a pilot...
Pulmatrix, Inc., (NASDAQ: PULM) today announced that its Chief Executive Officer, Robert Clarke, will present an overview of the company, its promising inhaled drug delivery technology, and its...